Venezuelan equine encephalitis virus vaccine candidate (V3526) safety, immunogenicity and efficacy in horses (Q45408093)

14 December 2017

Venezuelan equine encephalitis virus vaccine candidate (V3526) safety, immunogenicity and efficacy in horses (English)

1 reference

Venezuelan equine encephalitis

14 December 2017

1 reference

1 reference

based on heuristic

inferred from title

Venezuelan equine encephalitis virus

object named as

Venezuelan equine encephalitis virus

1 reference

8

Ann M Powers

1 reference

14 December 2017

9

Richard A Bowen

1 reference

14 December 2017

Donald L Fine

1

1 reference

14 December 2017

Brian A Roberts

2

1 reference

14 December 2017

Max L Teehee

3

1 reference

14 December 2017

Sara J Terpening

4

1 reference

14 December 2017

Cindy L H Kelly

5

1 reference

14 December 2017

Janae L Raetz

6

1 reference

14 December 2017

Dale C Baker

7

1 reference

14 December 2017

language of work or name

English

0 references

publication date

27 October 2006

1 reference

14 December 2017

1 reference

14 December 2017

25

1 reference

14 December 2017

10

1 reference

14 December 2017

1868-1876

1 reference

Venezuelan equine encephalitis

14 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.030

Antigenic variants of Venezuelan equine encephalitis virus: their geographic distribution and epidemiologic significance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.030

Attenuating mutations in the E2 glycoprotein gene of Venezuelan equine encephalitis virus: construction of single and multiple mutants in a full-length cDNA clone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.030

Attenuated mutants of Venezuelan equine encephalitis virus containing lethal mutations in the PE2 cleavage signal combined with a second-site suppressor mutation in E1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.030

Onset and duration of protective immunity to IA/IB and IE strains of Venezuelan equine encephalitis virus in vaccinated mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.030

Genetically engineered, live attenuated vaccines for Venezuelan equine encephalitis: testing in animal models

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.030

Genetically engineered, live, attenuated vaccines protect nonhuman primates against aerosol challenge with a virulent IE strain of Venezuelan equine encephalitis virus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.030

Enzootic and Epizootic Venezuelan Equine Encephalomyelitis Virus in Horses Infected by Peripheral and Intrathecal Routes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.030

Venezuelan equine encephalitis-specific immunoglobulin responses: live attenuated TC-83 versus inactivated C-84 vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.030

TC-83 Venezuelan equine encephalitis vaccine exposure during pregnancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.030

Venezuelan Equine encephalitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.030

Evaluation in humans of a new, inactivated vaccine for Venezuelan equine encephalitis virus (C-84)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.030

Long-term duration of detectable neutralizing antibodies after administration of live-attenuated VEE vaccine and following booster vaccination with inactivated VEE vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.030

Experimental infection of horses with enzootic and epizootic strains of Venezuelan equine encephalomyelitis virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.030

Isolation of the vaccine strain of Venezuelan equine encephalomyelitis virus from mosquitoes in Louisiana

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.030

Venezuelan equine encephalitis virus vaccines induce mucosal IgA responses and protection from airborne infection in BALB/c, but not C3H/HeN mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.030

Improved mucosal protection against Venezuelan equine encephalitis virus is induced by the molecularly defined, live-attenuated V3526 vaccine candidate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.030

Comparative neurovirulence and tissue tropism of wild-type and attenuated strains of Venezuelan equine encephalitis virus administered by aerosol in C3H/HeN and BALB/c mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.030

Limited potential for mosquito transmission of genetically engineered, live-attenuated Venezuelan equine encephalitis virus vaccine candidates.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.030

Re-emergence of epidemic Venezuelan equine encephalomyelitis in South America. VEE Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.030

Comparative neurovirulence of attenuated and non-attenuated strains of Venezuelan equine encephalitis virus in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.030

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2006.10.030

1 reference

14 December 2017

1 reference